Clinical Trial: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Study Status: ACTIVE_NOT_RECRUITING
Recruit Status: ACTIVE_NOT_RECRUITING
Condition: Refractory Metastatic Colorectal Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With Advanced Microsatellite Stable and Mismatch Repair Pr
Brief Summary:
This is an open-label, nonrandomized, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
Read more